Acute spinal cord injury (SCI) produces tissue damage that continues to evolve days and
weeks after the initial insult, with corresponding functional impairments. Reducing the extent …

This study was initiated due to an NIH “Facilities of Research—Spinal Cord Injury” contract
to support independent replication of published studies that could be considered for a …

We examined the effects of minocycline, an anti-inflammatory drug, on functional recovery
following spinal cord injury (SCI). Rats received a mild, weight-drop contusion injury to the …

Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline.
Animal studies and early clinical trials support its use in several neurological diseases. In …

Minocycline, a clinically used tetracycline for over 40 years, crosses the blood–brain barrier
and prevents caspase up‐regulation. It reduces apoptosis in mouse models of Huntington's …

Minocycline has been demonstrated to be neuroprotective after spinal cord injury (SCI).
However, the cellular consequences of minocycline treatment on the secondary injury …

Minocycline hydrochloride (MH), a semi-synthetic tetracycline derivative, is a clinically
available antibiotic and anti-inflammatory drug that also exhibits potent neuroprotective …

Minocycline is currently under development as a neuroprotective agent in many different
brain diseases. In more than a dozen experimental investigations in various models of brain …

Initial studies conducted on the neuroprotective effects of minocycline, a second-generation
tetracycline, in experimental models of neurodegeneration gave promising results. However …

Spinal cord injury (SCI) causes a permanent neurological disability, and no satisfactory
treatment is currently available. After SCI, pro-nerve growth factor (proNGF) is known to play …